OBJECTIVE: To assess human papillomavirus (HPV) prevalence and distribution among French women with normal and pathologic cytology findings. METHODS: A genomic DNA microarray assay enabling the detection of 35 different HPV genotypes was used for in vitro diagnosis, as a complement to Papanicolaou screening, to test 785 women who attended the gynecology department of a hospital in Lyon, France. RESULTS: Pathologic and normal cytology findings were obtained for 260 (33.1%) and 302 (38.5%) of the 785 women, respectively, whereas 223 (28.4%) results were inconclusive. HPV infection and multiple infection were significantly more prevalent (P<0.001) in the population with pathologic findings (90.0% and 41.9%, respectively) than in the population with normal cytology findings (48.3% and 20.2%, respectively). Overall, the 4 most frequent HPV genotypes were HPV-16 (14.8%), HPV-53 (9.0%), HPV-31 (8.7%), and HPV-51 (7.5%), whereas HPV-18 (3.8%), HPV-6 (2.9%), and HPV-11 (0.4%) were less common. The HPV genotypes included in the quadrivalent vaccination had a prevalence of 20.6% among all women and 30.4% among those with pathologic findings. CONCLUSION: The present data indicate a reduced direct impact of HPV vaccination in the study population owing to a low prevalence of HPV-18 and a high prevalence of HPV-53, HPV-31, and HPV-51.
OBJECTIVE: To assess human papillomavirus (HPV) prevalence and distribution among French women with normal and pathologic cytology findings. METHODS: A genomic DNA microarray assay enabling the detection of 35 different HPV genotypes was used for in vitro diagnosis, as a complement to Papanicolaou screening, to test 785 women who attended the gynecology department of a hospital in Lyon, France. RESULTS: Pathologic and normal cytology findings were obtained for 260 (33.1%) and 302 (38.5%) of the 785 women, respectively, whereas 223 (28.4%) results were inconclusive. HPV infection and multiple infection were significantly more prevalent (P<0.001) in the population with pathologic findings (90.0% and 41.9%, respectively) than in the population with normal cytology findings (48.3% and 20.2%, respectively). Overall, the 4 most frequent HPV genotypes were HPV-16 (14.8%), HPV-53 (9.0%), HPV-31 (8.7%), and HPV-51 (7.5%), whereas HPV-18 (3.8%), HPV-6 (2.9%), and HPV-11 (0.4%) were less common. The HPV genotypes included in the quadrivalent vaccination had a prevalence of 20.6% among all women and 30.4% among those with pathologic findings. CONCLUSION: The present data indicate a reduced direct impact of HPV vaccination in the study population owing to a low prevalence of HPV-18 and a high prevalence of HPV-53, HPV-31, and HPV-51.
Authors: R Ghedira; W Mahfoudh; S Hadhri; S Gabbouj; I Bouanene; H Khairi; A Chaieb; R Khelifa; N Bouaouina; S Remadi; A A Elmi; D Bansal; A A Sultan; R Faleh; A Zakhama; L Chouchane; E Hassen Journal: Infect Agent Cancer Date: 2016-12-01 Impact factor: 2.965
Authors: Maria do Desterro Soares Brandão Nascimento; Flávia Castello Branco Vidal; Marcos Antonio Custódio Neto da Silva; José Eduardo Batista; Maria do Carmo Lacerda Barbosa; Walbert Edson Muniz Filho; Geusa Felipa de Barros Bezerra; Graça Maria de Castro Viana; Rebeca Costa Castelo Branco; Luciane Maria Oliveira Brito Journal: BMC Womens Health Date: 2018-01-02 Impact factor: 2.809